ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

erfonrilimab

Also written as “KN046”, “GT90001+KN046” and “KN046 (PD-L1/CTLA4 BsAb)”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Thymoma · Lymphoma · Triple Negative Breast Neoplasms, led by 4 companies.

Drug pageErfonrilimab: every studyAll 21 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jul 13, 202014 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Alphamab Oncology111 open or runningphase 3since Jul 13, 2020May 8, 2018none ahead
Suzhou Kintor Pharmaceuticalits history only11 open or runningphase 2since Jul 5, 2021Jul 5, 2021none ahead
Suzhou Zelgen Biopharmaceuticalsits history only10 open or runningphase 2since Oct 29, 2020Oct 29, 2020none ahead
Zhejiang Raygene Pharmaceuticalsits history only10 open or runningphase 2since Feb 13, 2025Feb 13, 2025none ahead

Also a collaborator on its studies: Sunshine Lake Pharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. May 8, 2018First study: phase 1 study in Advanced Solid TumorsFirst studyNCT03529526 · 21 enrolled · Australia
  2. Oct 31, 2018Phase 1 study in LymphomaNCT03733951 · 139 enrolled · China
  3. Feb 1, 2019Phase 2 study in Carcinoma, Non-Small-Cell LungNCT03838848 · 120 enrolled · China
  4. Mar 7, 20192 phase 2 studiesNCT03872791, NCT03925870
  5. Jul 7, 2020Phase 2 study in ThymomaNCT04469725 · 95 enrolled · China
  6. Jul 13, 2020Phase 3 study in Squamous Non-small-cell Lung CancerNCT04474119 · 482 enrolled · China
  7. Oct 19, 2020Phase 2 study in Advanced HCCNCT04601610 · 6 enrolled · China
  8. Dec 19, 2020Named erfonrilimabINNProposed as its International Nonproprietary Name in WHO's List 124 · before, KN046
  9. Jul 16, 2021Phase 3 study in Advanced Non-small Cell Lung CancerNCT05001724 · 16 enrolled · China
  10. Nov 26, 2021Phase 3 study in Advanced Pancreatic Ductal AdenocarcinomaNCT05149326 · 408 enrolled · China
  11. Jun 12, 2022Phase 2 study in Advanced Non-small Cell Lung CancerNCT05420220 · 95 enrolled · China

TargetBeta

CD274 →CTLA4 →read by rule
“A bispecific monoclonal antibody directed against both the immunosuppressive ligand, programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), ”NCIt, by rule
“Cytotoxic T-lymphocyte protein 4 inhibitor; Programmed cell death 1 ligand 1 inhibitor”ChEMBL 37, by rule

Studies

All 11 Alphamab Oncology leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05420220Advanced Non-small Cell Lung Cancer · China2CompletedDec 31, 202495
NCT05149326Advanced Pancreatic Ductal Adenocarcinoma · China3Active, not recruitingApr 30, 2024408
NCT05001724Advanced Non-small Cell Lung Cancer · China3TerminatedFeb 13, 202316
NCT04601610Advanced HCC · China2TerminatedMay 30, 20226
NCT04474119Squamous Non-small-cell Lung Cancer · China3UNKNOWNAug 30, 2022482
NCT04469725Thymoma · China2TerminatedJul 7, 202395
NCT03925870Esophageal Squamous Cell Carcinoma · China2CompletedAug 26, 202145
NCT03872791Triple Negative Breast Neoplasms · China2CompletedAug 16, 202252
NCT03838848Carcinoma, Non-Small-Cell Lung · China2TerminatedJul 30, 2022120
NCT03733951Lymphoma · China1CompletedJan 3, 2023139
NCT03529526Advanced Solid Tumors · Australia1UNKNOWNOct 30, 201921

How it is read

Names in the registry

  • “KN046”, 11 entries
  • “GT90001+KN046”, 4 entries
  • “KN046 (PD-L1/CTLA4 BsAb)”, 2 entries
  • “KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection)”, 1 entry
  • “KN046 Injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.